How This Company’s Rare Plant Expertise Could Potentially Disrupt a Multi-Billion Dollar Market (1)
See why now could be the best time to start your research on InMed Pharmaceuticals Inc. (Nasdaq: INM).
How Rare Canna-bi-noids Are Transforming the Pharmaceutical Landscape…(1)
Canna-bi-noids, the chemical compounds found in the canna-bis plant, have long intrigued scientists and medical researchers. While the well-known canna-bi-noids like canna-bi-diol (C-B-D) and tetrahydrocanna-bi-nol (T-H-C) have stolen the limelight, there exists a vast world of over 200 lesser-known canna-bi-noids, each with unique properties and potential therapeutic benefits. Among these underexplored compounds are canna-bi-gerol (CBG), canna-binol (CBN), tetrahydrocannabivarin (T-H-CV), and many more. What sets these rare canna-bi-noids apart is their remarkable medical potential without the mind-altering effects associated with T-H-C. (1)
Unveiling the ECS Connection (1) Central to understanding the impact of rare canna-bi-noids is grasping the role of the endocanna-bi-noid system (ECS) within our bodies. Comprising receptors, enzymes, and endocanna-bi-noids, the ECS regulates vital functions such as sleep, mood, appetite, memory, and fertility. When canna-bi-noids interact with the ECS, they trigger a range of beneficial effects, promoting balance and harmony within the body.
Endocanna-bi-noids, naturally produced by the body, facilitate proper internal function. Receptors for these endocanna-bi-noids are distributed throughout the body, serving as signaling points for ECS activity. Enzymes come into play by breaking down endocanna-bi-noids once their role is fulfilled, maintaining the ECS’s dynamic equilibrium.
A Healthcare Transformation in the Making (1) Emerging studies have illuminated the potential of canna-bi-noids in addressing a wide array of medical conditions. Several clinical trials on canna-bi-noids have yielded promising data on their therapeutic benefits. For instance, C-B-D has been approved for epilepsy and is being studied for other disorders such as anxiety. These findings are just the tip of the iceberg, hinting at the vast potential canna-bi-noids hold in improving health and well-being.
The potential impact of rare canna-bi-noids on the medical industry is immense. As these compounds become more accessible and affordable, they will unlock new avenues for medical treatment and wellness. Rare canna-bi-noids like CBG/CBGA, CBN/CBNA, T-H-CV/T-H-CVA, and T-H-CA have shown compelling evidence of their health benefits.
Endocanna-bi-noids, naturally produced by the body, facilitate proper internal function. Receptors for these endocanna-bi-noids are distributed throughout the body, serving as signaling points for ECS activity. Enzymes come into play by breaking down endocanna-bi-noids once their role is fulfilled, maintaining the ECS’s dynamic equilibrium.
The potential impact of rare canna-bi-noids on the medical industry is immense. As these compounds become more accessible and affordable, they will unlock new avenues for medical treatment and wellness. Rare canna-bi-noids like CBG/CBGA, CBN/CBNA, T-H-CV/T-H-CVA, and T-H-CA have shown compelling evidence of their health benefits.
Among the pioneering companies in this transformative field is InMed Pharmaceuticals Inc. (Nasdaq: INM).
As the pharmaceutical industry undergoes this profound shift driven by rare canna-bi-noids, InMed Pharmaceuticals Inc. (Nasdaq: INM) stands as one of the little-known yet promising companies to keep a close eye on.
With its commitment to research, development, and innovation in canna-bi-noid-based pharmaceuticals, InMed Pharmaceuticals Inc. (Nasdaq: INM) may play a significant role in shaping the future of healthcare.
Keep reading to see why InMed Pharmaceuticals Inc. (Nasdaq: INM) needs to be at the top of your daily watch list…
As the pharmaceutical industry undergoes this profound shift driven by rare canna-bi-noids, InMed Pharmaceuticals Inc. (Nasdaq: INM) stands as one of the little-known yet promising companies to keep a close eye on.
With its commitment to research, development, and innovation in canna-bi-noid-based pharmaceuticals, InMed Pharmaceuticals Inc. (Nasdaq: INM) may play a significant role in shaping the future of healthcare.
Keep reading to see why InMed Pharmaceuticals Inc. (Nasdaq: INM) needs to be at the top of your daily watch list…
7 Reasons Why InMed Pharmaceuticals Inc. (Nasdaq: INM) Could Be Poised For Significant Upside Potential Ahead of 2024…
1. Active Chart
InMed Pharmaceuticals Inc. (Nasdaq: INM) has demonstrated the potential for significant upside potential with a 52-week range of $.2913 - $3.03. Not that any returns to previous highs are certain, but the potential for 940% upside suggests a strong reason to begin your research on this company after their shares fell from their 52-week high on 1/4/2023 to a recent 52-week low bounce on 11/20/2023. (6)
2. Groundbreaking Potential:
With its innovative approach to Alzheimer's disease treatment through INM-901 and its pioneering work in the treatment of Age-Related Macular Degeneration with INM-089, InMed Pharmaceuticals Inc. (Nasdaq: INM) presents groundbreaking potential across multiple therapeutic fronts. INM-901, in particular, has demonstrated unique pharmacological effects in preclinical studies, including neuroprotection and enhanced neuronal function. Exploring the research on INM-901 and INM-089 may reveal the prospect of substantial breakthroughs in the fields of Alzheimer's and AMD treatments. (17)(20)
3. Revenue-Generating Subsidiary
Having a revenue-generating subsidiary, InMed Pharmaceuticals Inc. (Nasdaq: INM) enjoys a unique advantage among pharmaceutical companies. This subsidiary provides a financial foundation for enhancing the company's ability to fund ongoing research and development activities without relying solely on external financing. (5)(11)
4. Expertise in Canna-bi-noid Manufacturing
With the growing interest in canna-bi-noids for various medical and market sectors, InMed Pharmaceuticals Inc. (Nasdaq: INM) has significant expertise in developing innovative manufacturing approaches for producing canna-bi-noids. This know-how positions InMed well to produce canna-bi-noids for various market sectors. (11)
5. Significant Valuation Gap
Despite its promising pipeline and revenue-generating subsidiary, InMed Pharmaceuticals Inc. (Nasdaq: INM)’s market capitalization remains below $5 million as of 11/17/2023, according to the company’s corporate presentation. (22) This valuation gap suggests that the company could be trading well below its true intrinsic value, making it an intriguing research opportunity for those seeking undervalued assets.
6. Listed on Nasdaq Exchange:
Being listed on a major exchange brings increased visibility, liquidity, and credibility, offering distinct advantages for a company. InMed Pharmaceuticals Inc. (Nasdaq: INM)'s presence on the Nasdaq exchange sets it apart from many cann-a-bis-related companies, which often trade on smaller or less-regulated exchanges. (13)
7. Rare Canna-bi-noid Production
Through its wholly owned subsidiary, BayMedica, InMed Pharmaceuticals Inc. (Nasdaq: INM) produces highly pure rare canna-bi-noids such as d9-T-H-CV, CBC, C-B-DV, and CBT for the consumer health and wellness industry. As the demand for these unique canna-bi-noids grows, InMed could be well-positioned to supply these valuable compounds to an expanding market. (11)
Could InMed Pharmaceuticals Inc. (Nasdaq: INM) Have Over 940%in Potential Upside? (6)
InMed Pharmaceuticals Inc. (Nasdaq: INM) is demonstrating the potential for significant upside potential with a 52-week range of $.2913 – $3.03. Not that any returns to previous highs are certain, but the potential for 940% upside suggests a strong reason to begin your research on this company after their shares fell from their 52-week high on 1/4/2023 and more and recently bounced off their 52-week low on 11/20/2023. (6)
According to StockCharts.com, InMed Pharmaceuticals Inc. (Nasdaq: INM) is currently displaying significant upside potential to the following moving averages as of 11/28/2023:(8)
According to StockCharts.com, InMed Pharmaceuticals Inc. (Nasdaq: INM) is currently displaying significant upside potential to the following moving averages as of 11/28/2023:(8)
A return to any previous highs isn’t certain, but it’s important to note the potential upside from current levels.
Despite its promising pipeline and revenue-generating subsidiary, InMed Pharmaceuticals Inc. (Nasdaq: INM) is considered a “nano-cap” stock because its market capitalization remains below $5 million according to the company’s corporate presentation. (22).
Despite its promising pipeline and revenue-generating subsidiary, InMed Pharmaceuticals Inc. (Nasdaq: INM) is considered a “nano-cap” stock because its market capitalization remains below $5 million according to the company’s corporate presentation. (22).
This valuation gap suggests that the company could be trading well below its true intrinsic value, making it an intriguing research opportunity.
In general, nano-cap companies have market capitalizations of less than $50 million. (14) Because nano-cap stocks are significantly smaller than mid-cap or large-cap companies, they have a higher potential to change valuation quickly. (15)
Nano-cap stocks may be overlooked by the market, as they often receive little attention from analysts and institutions. This can provide excellent research opportunities for individuals who are seeking to discover hidden gems. These small and often little-known companies may bring major improvements to existing products and services as well as introducing new products, using innovation to accelerate growth. (16)
This is why things could get very interesting and why you need to start your research on InMed Pharmaceuticals Inc. (Nasdaq: INM).
In general, nano-cap companies have market capitalizations of less than $50 million. (14) Because nano-cap stocks are significantly smaller than mid-cap or large-cap companies, they have a higher potential to change valuation quickly. (15)
Nano-cap stocks may be overlooked by the market, as they often receive little attention from analysts and institutions. This can provide excellent research opportunities for individuals who are seeking to discover hidden gems. These small and often little-known companies may bring major improvements to existing products and services as well as introducing new products, using innovation to accelerate growth. (16)
This is why things could get very interesting and why you need to start your research on InMed Pharmaceuticals Inc. (Nasdaq: INM).
Unveiling InMed Pharmaceuticals Inc. (Nasdaq: INM): Pioneering Rare Canna-bi-noid Advancements (11)
In the ever-evolving landscape of pharmaceuticals, InMed Pharmaceuticals Inc. (Nasdaq: INM) has emerged as a trailblazer. This innovative company is at the forefront of dr-ug discovery and development, specializing in the realm of rare canna-bi-noids. (11)
A Pure-Play Rare Canna-bi-noid Company (11) InMed Pharmaceuticals Inc. (Nasdaq: INM) is a pure-play rare canna-bi-noid company, dedicated to unraveling the therapeutic potential of canna-bi-noids. With a focus on pharmaceutical research and development (R&D), InMed’s endeavors encompass a wide range of pharmaceutical programs targeting various medical conditions. Their specialized areas of interest include dermatological, ocular, and neurodegenerative diseases.
Rare Canna-bi-noid Expertise Across Several Areas (11)
- Pharmaceutical Programs: InMed boasts an impressive pipeline of pharmaceutical programs. Their commitment to dr-ug development spans a spectrum of medical conditions, addressing unmet needs in dermatology, ophthalmology, and neurodegenerative diseases.
- Screening of Therapeutic Candidates: InMed actively screens therapeutic candidates, seeking out the most promising rare canna-bi-noids for further research and development.
- Canna-bi-noid Analogs Development: The company is not content with naturally occurring canna-bi-noids alone; they're also pioneering the development of proprietary canna-bi-noid analogs. InMed’s division has an extensive library of canna-bi-noid new chemical entities for pharmaceutical development, aimed at targeting diverse clinical indications. Years of canna-bi-noid research and knowledge have led to a myriad of patentable canna-bi-noid analogs.
- Chemical and Biosynthesis Expertise: InMed Pharmaceuticals possesses unmatched proficiency in both chemical synthesis and biosynthesis of canna-bi-noids, enabling them to produce these compounds efficiently and at scale.
- B2B Supplier to Health and Wellness Industry: Through its subsidiary, BayMedica, InMed is a leading supplier of rare canna-bi-noids to the health and wellness sector, contributing to the growth of this emerging industry.
- A Diverse Patent Portfolio: InMed has a strong patent position that includes 13 patent families covering manufacturing, methods of use and formulation of rare canna-bi-noids. The company's portfolio includes a broad patent application for the creation of several variations of novel canna-bi-noid compounds, biosynthetic pathway and semi-synthetic production of both natural canna-bi-noids and analogs, methods for manufacturing and uses of specific rare canna-bi-noids.
Canna-bi-noid Drug Development Programs (11)
- InMed Pharmaceuticals Inc. (Nasdaq: INM)’s commitment to rare canna-bi-noids is reflected in its impressive lineup of dr-ug development programs:
Naturally-Occurring Canna-bi-noids: INM-755 (Epidermolysis Bullosa)
- Phase 2 clinical trial completed, showcasing positive results in enhancing anti-itch activity.
- Pursuing partnerships for further development.
Naturally-Occurring Canna-bi-noids: INM-088 (Glaucoma)
- Demonstrated the ability to lower intraocular pressure (IOP) in the front of the eye.
- Exhibited neuroprotection properties in the back of the eye.
- Planning for IND-enabling toxicology studies.
Canna-bi-noid Analogs: INM-900 Series (Neurodegenerative Diseases)
- In vivo studies showing improved neuronal function and neuroprotection.
- Paving the way for potential breakthroughs in treating neurodegenerative diseases.
With a diverse portfolio of pharmaceutical programs, rare canna-bi-noid expertise, and a dedication to forging strategic partnerships, the company is poised to unlock the full potential of canna-bi-noid medicines.
As the world witnesses the ongoing evolution of canna-bi-noid-based therapies, InMed’s pioneering work promises new horizons for patients and offers a glimpse into the future of pharmaceuticals, where rare canna-bi-noids play a pivotal role in addressing unmet medical needs.
As the world witnesses the ongoing evolution of canna-bi-noid-based therapies, InMed’s pioneering work promises new horizons for patients and offers a glimpse into the future of pharmaceuticals, where rare canna-bi-noids play a pivotal role in addressing unmet medical needs.
SUBSCRIBE TO OUR NEWSLETTER FOR MUST READ REPORTS & NEWS.
Getting the Right News Before Everyone Else Does, is FREE…
InMed Pharmaceuticals Inc. (Nasdaq: INM): Pioneering New Hope in Alzheimer's Disease Treatment with INM-901(17)
Alzheimer’s disease is a devastating neurodegenerative condition that affects millions of individuals worldwide, and it has long been one of the most challenging diseases to tackle in the field of medicine. However, there is a glimmer of hope on the horizon in the form of InMed Pharmaceuticals Inc. (Nasdaq: INM) and their groundbreaking Alzheimer’s disease drug candidate, INM-901.
InMed Pharmaceuticals recently made waves in the medical and pharmaceutical communities by announcing the selection of INM-901 as a lead candidate for the treatment of Alzheimer’s disease. This promising development comes on the heels of a series of successful preclinical proof-of-concept studies that have shown INM-901 to have unique and potent pharmacological effects in the context of Alzheimer’s disease.
The Promise of INM-901 (17)
One of the standout features of INM-901 is its ability to target multiple biological pathways associated with Alzheimer’s disease. Moreover, it has demonstrated the capacity to improve neuronal function by extending neurite length, which is a key indicator of enhanced neuronal performance.
In addition to these encouraging in vitro findings, INM-901 has also shown remarkable results in in vivo preclinical studies conducted in a validated Alzheimer’s disease treatment model. When compared to placebo-treated Alzheimer’s disease groups, those treated with INM-901 exhibited a trend toward improvement in various crucial areas:(17)
– Cognitive Function and Memory – Locomotor Activity – Anxiety-Based Behavior – Sound Awareness
These findings represent a significant breakthrough in Alzheimer’s disease research and offer newfound hope for individuals and families affected by this debilitating condition.
A Rigorous Candidate Selection Process (17)
The journey to discovering INM-901 began with InMed’s exploration of neuroprotective effects in their ocular disease/glaucoma development program (INM-088). This initial research led to the screening of multiple canna-bi-noids against various non-ocular neuron models, including those in the brain. Among these canna-bi-noids, one emerged as a standout candidate for protection against neurodegenerative diseases of the brain.
InMed’s research team further refined this candidate by developing several analogs to maximize its potential effects. Subsequent screening in Alzheimer’s disease assays identified two analogs that were then advanced to in vivo preclinical testing using a well-established Alzheimer’s proof-of-concept model. Based on the promising results of these preclinical tests, INM-901 emerged as the final candidate for continued pharmaceutical research and development.
Addressing the Limitations of Current Treatments (17)
The current landscape of Alzheimer’s disease treatments primarily focuses on managing symptoms related to memory and cognitive function through the reduction of beta-amyloid plaques. While these medications can slow the rate of cognitive decline, they do not reverse the disease’s effects or address the underlying neurodegeneration. Additionally, these treatments are associated with significant side effects, including brain inflammation and bleeding, necessitating regular brain scans.
In contrast, INM-901 offers the potential for disease-modifying effects, making it a promising candidate for Alzheimer’s disease treatment. By targeting multiple receptor systems and possessing the ability to cross the blood-brain barrier, INM-901 represents a multi-pronged approach to treating this complex neurological disorder.
Progress and Future Prospects (17)
InMed’s recent breakthrough in Alzheimer’s disease research is a testament to the dedication and innovation of their scientific team. Their progress includes filing international patents that acknowledge the potential use of rare canna-bi-noids and analogs, like INM-901, in the treatment of various neurodegenerative diseases, including Alzheimer’s.
A presentation at the Canadian Neuroscience Meeting showcased the ability of a specific rare canna-bi-noid to reduce amyloid toxicity and tau protein expression while promoting neuronal cell growth and neuritogenesis markers. These findings align with the critical targets in the potential treatment of neurodegenerative diseases like Alzheimer’s.
Dr. Eric Hsu, InMed’s Senior Vice President of Preclinical Research and Development, summed up the excitement surrounding INM-901, stating, “The most recent studies of INM-901 demonstrate promising disease-modifying effects in an Alzheimer’s disease treatment model. We are optimistic that the next stage of studies will continue to show how this canna-bi-noid analog can improve neuronal function, a potential breakthrough in Alzheimer’s treatment.” (17)
Alzheimer’s disease remains a significant unmet medical need, and INM-901 may hold the key to transforming the lives of those affected by this devastating condition. As InMed Pharmaceuticals continues to advance their research and development efforts, there is newfound hope that a breakthrough treatment for Alzheimer’s disease is on the horizon, offering solace to patients and their families.
InMed Pharmaceuticals recently made waves in the medical and pharmaceutical communities by announcing the selection of INM-901 as a lead candidate for the treatment of Alzheimer’s disease. This promising development comes on the heels of a series of successful preclinical proof-of-concept studies that have shown INM-901 to have unique and potent pharmacological effects in the context of Alzheimer’s disease.
In addition to these encouraging in vitro findings, INM-901 has also shown remarkable results in in vivo preclinical studies conducted in a validated Alzheimer’s disease treatment model. When compared to placebo-treated Alzheimer’s disease groups, those treated with INM-901 exhibited a trend toward improvement in various crucial areas:(17)
– Cognitive Function and Memory – Locomotor Activity – Anxiety-Based Behavior – Sound Awareness
These findings represent a significant breakthrough in Alzheimer’s disease research and offer newfound hope for individuals and families affected by this debilitating condition.
InMed’s research team further refined this candidate by developing several analogs to maximize its potential effects. Subsequent screening in Alzheimer’s disease assays identified two analogs that were then advanced to in vivo preclinical testing using a well-established Alzheimer’s proof-of-concept model. Based on the promising results of these preclinical tests, INM-901 emerged as the final candidate for continued pharmaceutical research and development.
In contrast, INM-901 offers the potential for disease-modifying effects, making it a promising candidate for Alzheimer’s disease treatment. By targeting multiple receptor systems and possessing the ability to cross the blood-brain barrier, INM-901 represents a multi-pronged approach to treating this complex neurological disorder.
A presentation at the Canadian Neuroscience Meeting showcased the ability of a specific rare canna-bi-noid to reduce amyloid toxicity and tau protein expression while promoting neuronal cell growth and neuritogenesis markers. These findings align with the critical targets in the potential treatment of neurodegenerative diseases like Alzheimer’s.
Dr. Eric Hsu, InMed’s Senior Vice President of Preclinical Research and Development, summed up the excitement surrounding INM-901, stating, “The most recent studies of INM-901 demonstrate promising disease-modifying effects in an Alzheimer’s disease treatment model. We are optimistic that the next stage of studies will continue to show how this canna-bi-noid analog can improve neuronal function, a potential breakthrough in Alzheimer’s treatment.” (17)
Alzheimer’s disease remains a significant unmet medical need, and INM-901 may hold the key to transforming the lives of those affected by this devastating condition. As InMed Pharmaceuticals continues to advance their research and development efforts, there is newfound hope that a breakthrough treatment for Alzheimer’s disease is on the horizon, offering solace to patients and their families.
InMed Pharmaceuticals Inc. (Nasdaq: INM): A Year of Achievements, Aims For Strong Start to 2024… (5)(18)
InMed Pharmaceuticals Inc. (Nasdaq: INM) has been at the forefront of innovation in the pharmaceutical industry, making significant strides in the research, development, manufacturing, and commercialization of rare canna-bi-noids and canna-bi-noid analogs. As we look back on the achievements of 2023 and the promising start to 2024, it’s clear that InMed is poised for a bright future. (5)(18)
A Recap of the Remarkable Fiscal Year 2023 (5)
The year 2023 was a remarkable one for InMed Pharmaceuticals Inc. (Nasdaq: INM), marked by impressive financial performance, clinical trial advancements, and an expanding pharmaceutical pipeline. Here are the key highlights:
Exceptional Financial Performance (5)
One of the standout achievements of 2023 was InMed’s exceptional financial performance. The company reported total sales for its subsidiary, BayMedica, of rare canna-bi-noids reaching an impressive $4.1 million for the fiscal year. This represented a remarkable 280% increase compared to the previous fiscal year, underscoring InMed’s ability to meet the growing demand for rare compounds effectively.
As of June 30, 2023, InMed Pharmaceuticals Inc. (Nasdaq: INM) boasted a robust financial position, with $9.0 million in cash, cash equivalents, and short-term investments. This financial strength provided the company with a solid foundation to support its ongoing operations and meet its capital expenditure requirements. (5)
Importantly, the fiscal year 2023 witnessed a significant reduction in InMed Pharmaceuticals Inc. (Nasdaq: INM)’s net loss, which amounted to $7.9 million, compared to a net loss of $18.6 million in the previous year. This substantial improvement signaled the company’s ability to generate growing revenue streams and its commitment to effective cost management. (5)
Advancements in Clinical Trials and Pharmaceutical Pipeline(5) Throughout 2023, InMed Pharmaceuticals Inc. (Nasdaq: INM) was actively involved in clinical trials, achieving noteworthy milestones. Here are the key highlights:
Epidermolysis Bullosa (EB) Trial: InMed successfully completed its Phase 2 clinical trial for the treatment of Epidermolysis Bullosa (EB). Although the trial did not yield statistically significant results, it demonstrated clinically meaningful anti-itch activity in a majority of participants, with 27.8% experiencing superior results compared to the control cream. This outcome prompted InMed to explore strategic partnership opportunities for the further development of INM-755 in EB treatment and other anti-itch indications with broader commercial potential.
Ocular Programs: InMed Pharmaceuticals Inc. (Nasdaq: INM) made substantial progress in its ocular programs, particularly in the treatment of glaucoma. The company actively conducted preclinical testing for a CBN-based eye drop formulation, positioning itself to address a significant market need.(5) Furthermore, InMed expanded its research to explore the potential of certain canna-bi-noids in neuroprotection of the eye and extended its focus to include the treatment of Age-Related Macular Degeneration (AMD).
Neurodegenerative Diseases Program: The most exciting development of 2023 was the launch of the INM-900 series program, dedicated to addressing neurodegenerative diseases such as Alzheimer’s, Huntington’s, and Parkinson’s. InMed Pharmaceuticals Inc. (Nasdaq: INM)’s research uncovered the potential of canna-bi-noids in providing neuroprotection, opening up promising avenues for the treatment of brain-related diseases. The company identified two canna-bi-noid analogs (INM-900 series) showing tremendous promise in the treatment of neurodegenerative diseases, setting the stage for further preclinical research.
First Quarter Fiscal 2024 Financial Results and Business Update (18)
With the successes of 2023 as a strong foundation, InMed Pharmaceuticals Inc. (Nasdaq: INM) is off to an impressive start in 2024. The company recently unveiled its first-quarter fiscal 2024 financial results, highlighting key developments and financial stability that bode well for the future. (18)
Financial Highlights (18)
In the first quarter of fiscal 2024, InMed recorded a net loss of $2.5 million, a notable improvement compared to the net loss of $3.5 million reported for the same quarter in the previous year. This demonstrates the company’s commitment to financial prudence and cost management.
Research and development and patents expenses for the first quarter of fiscal 2024 totaled $1.3 million, slightly down from $1.4 million during the same period in the previous year. However, the company anticipates increased research and development expenses in calendar year 2024 as it advances its preclinical work in INM-901 and conducts IND enabling studies in ocular disease.
General and administrative expenses amounted to $1.3 million for the first quarter of fiscal 2024, down from $1.6 million in the same period of the previous year. This decrease was mainly driven by changes in the InMed segment, including lower office and admin fees, accounting and legal fees, stock-based compensation expenses, regulatory fees, and consulting fees.
At the close of the quarter on September 30, 2023, InMed Pharmaceuticals held cash, cash equivalents, and short-term investments totaling $6.7 million. Following the close of the quarter, on October 26, 2023, the company successfully completed a $5.2 million financing, further enhancing its financial position.
The prudent management of expenses and strategic financing have provided InMed Pharmaceuticals with added financial stability, ensuring it can continue to advance its pharmaceutical pipeline candidates and meet its planned operating expenses and capital expenditure requirements into the third quarter of calendar year 2024.
Business Update (18)
InMed Pharmaceuticals has not only showcased its financial prowess but has also provided significant updates on its business operations:
Pharmaceutical Development Programs: InMed Pharmaceuticals continues to make significant progress in its neurodegenerative diseases program, particularly with INM-901, offering hope in Alzheimer’s treatment. The company is conducting advanced preclinical studies, covering critical aspects such as drug distribution, metabolism, pharmacokinetics, and pharmaceutical drug development activities like manufacturing and formulation.
In the dermatology program, INM-755 has displayed promising results in a Phase 2 clinical trial for the treatment of symptoms related to epidermolysis bullosa (EB). InMed is actively exploring partnership opportunities to advance INM-755.
BayMedica Commercial Subsidiary: BayMedica, the company’s commercial subsidiary, continues to experience robust year-over-year revenue growth. While there was a quarter-over-quarter decrease in revenue of 61%, mainly attributed to distributor order patterns and product mix, the company anticipates sustained growth as the market expands and brands innovate by incorporating new canna-bi-noid ingredients into their product offerings. (18)
InMed Pharmaceuticals is actively working to lower manufacturing costs, improve margins over time, and align production and inventory levels with sales demand and forecasts. (18)
Looking Ahead (18)
InMed Pharmaceuticals Inc. (Nasdaq: INM) has made significant strides in its pharmaceutical development programs, achieving promising results with INM-901 in Alzheimer’s disease and INM-755 in dermatology. Additionally, its commercial subsidiary, BayMedica, is experiencing remarkable revenue growth, positioning the company well for the future.
As the company moves forward into 2024, InMed Pharmaceuticals remains committed to innovation and breakthroughs in rare canna-bi-noids and canna-bi-noid analogs, benefiting both patients and industry stakeholders alike. The company’s financial stability, clinical advancements, and expanding pharmaceutical pipeline make it a key player in shaping the future of pharmaceuticals.
As of June 30, 2023, InMed Pharmaceuticals Inc. (Nasdaq: INM) boasted a robust financial position, with $9.0 million in cash, cash equivalents, and short-term investments. This financial strength provided the company with a solid foundation to support its ongoing operations and meet its capital expenditure requirements. (5)
Importantly, the fiscal year 2023 witnessed a significant reduction in InMed Pharmaceuticals Inc. (Nasdaq: INM)’s net loss, which amounted to $7.9 million, compared to a net loss of $18.6 million in the previous year. This substantial improvement signaled the company’s ability to generate growing revenue streams and its commitment to effective cost management. (5)
Advancements in Clinical Trials and Pharmaceutical Pipeline(5) Throughout 2023, InMed Pharmaceuticals Inc. (Nasdaq: INM) was actively involved in clinical trials, achieving noteworthy milestones. Here are the key highlights:
Epidermolysis Bullosa (EB) Trial: InMed successfully completed its Phase 2 clinical trial for the treatment of Epidermolysis Bullosa (EB). Although the trial did not yield statistically significant results, it demonstrated clinically meaningful anti-itch activity in a majority of participants, with 27.8% experiencing superior results compared to the control cream. This outcome prompted InMed to explore strategic partnership opportunities for the further development of INM-755 in EB treatment and other anti-itch indications with broader commercial potential.
Ocular Programs: InMed Pharmaceuticals Inc. (Nasdaq: INM) made substantial progress in its ocular programs, particularly in the treatment of glaucoma. The company actively conducted preclinical testing for a CBN-based eye drop formulation, positioning itself to address a significant market need.(5) Furthermore, InMed expanded its research to explore the potential of certain canna-bi-noids in neuroprotection of the eye and extended its focus to include the treatment of Age-Related Macular Degeneration (AMD).
Neurodegenerative Diseases Program: The most exciting development of 2023 was the launch of the INM-900 series program, dedicated to addressing neurodegenerative diseases such as Alzheimer’s, Huntington’s, and Parkinson’s. InMed Pharmaceuticals Inc. (Nasdaq: INM)’s research uncovered the potential of canna-bi-noids in providing neuroprotection, opening up promising avenues for the treatment of brain-related diseases. The company identified two canna-bi-noid analogs (INM-900 series) showing tremendous promise in the treatment of neurodegenerative diseases, setting the stage for further preclinical research.
Research and development and patents expenses for the first quarter of fiscal 2024 totaled $1.3 million, slightly down from $1.4 million during the same period in the previous year. However, the company anticipates increased research and development expenses in calendar year 2024 as it advances its preclinical work in INM-901 and conducts IND enabling studies in ocular disease.
General and administrative expenses amounted to $1.3 million for the first quarter of fiscal 2024, down from $1.6 million in the same period of the previous year. This decrease was mainly driven by changes in the InMed segment, including lower office and admin fees, accounting and legal fees, stock-based compensation expenses, regulatory fees, and consulting fees.
At the close of the quarter on September 30, 2023, InMed Pharmaceuticals held cash, cash equivalents, and short-term investments totaling $6.7 million. Following the close of the quarter, on October 26, 2023, the company successfully completed a $5.2 million financing, further enhancing its financial position.
The prudent management of expenses and strategic financing have provided InMed Pharmaceuticals with added financial stability, ensuring it can continue to advance its pharmaceutical pipeline candidates and meet its planned operating expenses and capital expenditure requirements into the third quarter of calendar year 2024.
Pharmaceutical Development Programs: InMed Pharmaceuticals continues to make significant progress in its neurodegenerative diseases program, particularly with INM-901, offering hope in Alzheimer’s treatment. The company is conducting advanced preclinical studies, covering critical aspects such as drug distribution, metabolism, pharmacokinetics, and pharmaceutical drug development activities like manufacturing and formulation.
In the dermatology program, INM-755 has displayed promising results in a Phase 2 clinical trial for the treatment of symptoms related to epidermolysis bullosa (EB). InMed is actively exploring partnership opportunities to advance INM-755.
BayMedica Commercial Subsidiary: BayMedica, the company’s commercial subsidiary, continues to experience robust year-over-year revenue growth. While there was a quarter-over-quarter decrease in revenue of 61%, mainly attributed to distributor order patterns and product mix, the company anticipates sustained growth as the market expands and brands innovate by incorporating new canna-bi-noid ingredients into their product offerings. (18)
InMed Pharmaceuticals is actively working to lower manufacturing costs, improve margins over time, and align production and inventory levels with sales demand and forecasts. (18)
As the company moves forward into 2024, InMed Pharmaceuticals remains committed to innovation and breakthroughs in rare canna-bi-noids and canna-bi-noid analogs, benefiting both patients and industry stakeholders alike. The company’s financial stability, clinical advancements, and expanding pharmaceutical pipeline make it a key player in shaping the future of pharmaceuticals.
BayMedica's Strong Commercial Growth (5)
InMed Pharmaceuticals Inc. (Nasdaq: INM)’s subsidiary, BayMedica, has been experiencing robust revenue growth, with sales of non-intoxicating rare canna-bi-noids in the health and wellness sector reaching $4.1 million for fiscal year 2023. This represents a remarkable 280% increase compared to the previous year. Importantly, BayMedica achieved three consecutive quarters of substantial revenue growth, with Q2, Q3, and Q4 of 2023 seeing impressive increases of 46%, 100%, and 123%, respectively. Although Q1 fiscal 2024 saw a drop in revenue it still represented a 181% increase over the same period in the previous year.
While revenue fluctuations are expected in this emerging market, BayMedica’s recent performance underscores its potential in the rare canna-bi-noids sector.
To support its growth, BayMedica has optimized and scaled up manufacturing processes, secured additional sources of raw materials, and established downstream purification partnerships. These efforts ensure the consistent supply of high-purity rare canna-bi-noids with minimal batch-to-batch variations.
While revenue fluctuations are expected in this emerging market, BayMedica’s recent performance underscores its potential in the rare canna-bi-noids sector.
To support its growth, BayMedica has optimized and scaled up manufacturing processes, secured additional sources of raw materials, and established downstream purification partnerships. These efforts ensure the consistent supply of high-purity rare canna-bi-noids with minimal batch-to-batch variations.
Looking Ahead (5)
InMed Pharmaceuticals Inc. (Nasdaq: INM)’s accomplishments in fiscal year 2023 reflect its commitment to advancing the field of rare canna-bi-noids and canna-bi-noid analogs. With an expanding pharmaceutical pipeline, and a subsidiary making significant inroads in the health and wellness sector, the company is well-positioned for continued growth and innovation.
In the words of Eric A. Adams, InMed’s Chief Executive Officer, “We remain optimistic about the long-term growth potential in the rare canna-bi-noids sector as the business dynamics and commercial opportunities continue to mature.”(5)
In the words of Eric A. Adams, InMed’s Chief Executive Officer, “We remain optimistic about the long-term growth potential in the rare canna-bi-noids sector as the business dynamics and commercial opportunities continue to mature.”(5)
Unlocking the Potential of Rare Canna-bi-noids: InMed Pharmaceuticals Inc. (Nasdaq: INM) 11
InMed Pharmaceuticals Inc. (Nasdaq: INM) has embarked on a pioneering journey in the world of pharmaceuticals, with a primary focus on the research and development of rare canna-bi-noids. Leveraging the inherent therapeutic properties of canna-bi-noids found in the canna-bis plant, InMed is at the forefront of dr-ug development programs aimed at addressing a wide range of medical conditions.
A Diverse Portfolio of Canna-bi-noid Drug Development Programs (11)
InMed Pharmaceuticals Inc. (Nasdaq: INM)’s (11) commitment to advancing the field of canna-bi-noid-based pharmaceuticals is evident through its diverse portfolio of dr-ug development programs. These programs span various phases of research, preclinical, and clinical trials, offering promising solutions to a multitude of health challenges.
Naturally-Occurring Canna-bi-noids: INM-755 (11) One of InMed Pharmaceuticals Inc. (Nasdaq: INM)’s notable achievements is the development of INM-755, for the treatment of Epidermolysis bullosa (EB). EB is a rare genetic disorder characterized by fragile skin, leading to severe blistering and skin erosions. In a Phase 2 clinical trial, INM-755 demonstrated a positive indication of enhanced anti-itch activity compared to a control cream. While the trial did not yield statistically significant results, the clinically meaningful improvement in anti-itch activity has opened doors for further development. InMed is actively pursuing strategic partnerships to advance the potential of INM-755 in the treatment of EB and other anti-itch indications.
INM’s Ocular Disease Programs (11) InMed Pharmaceuticals Inc. (Nasdaq: INM)’s foray into ocular diseases is exemplified by INM-088, targeting glaucoma. Glaucoma is a leading cause of irreversible blindness worldwide, characterized by increased intraocular pressure that can damage the optic nerve. In preclinical studies, INM-088 has showcased promising results, effectively lowering intraocular pressure in the front of the eye. Additionally, it has demonstrated neuroprotection properties in the back of the eye, offering potential benefits in preserving vision.
Exploring Therapeutic Uses with Other R&D In addition to the highlighted programs, InMed Pharmaceuticals Inc. (Nasdaq: INM) is actively engaged in ongoing research and development (R&D) efforts to screen for therapeutic uses of canna-bi-noids. The company’s commitment to innovation and exploration is a testament to its dedication to harnessing the full potential of these compounds.
InMed Pharmaceuticals Inc. (Nasdaq: INM)’s (11) commitment to advancing the field of canna-bi-noid-based pharmaceuticals is evident through its diverse portfolio of dr-ug development programs. These programs span various phases of research, preclinical, and clinical trials, offering promising solutions to a multitude of health challenges.
Strategic Partnerships: Fueling the Future (11)
As InMed Pharmaceuticals Inc. (Nasdaq: INM) advances its canna-bi-noid dr-ug development programs, strategic partnerships play a pivotal role in shaping the future of these therapies. Collaborations with industry leaders and innovators are poised to accelerate the journey towards bringing these groundbreaking treatments to patients in need.
Latest Development
InMed Pharmaceuticals Inc. (Nasdaq: INM) Expands Its Pipeline with INM-089: A Promising AMD Treatment… (20)
InMed Pharmaceuticals Inc. (Nasdaq: INM) continues to make significant strides in the field of pharmaceutical research and development with the recent announcement of its new ocular pharmaceutical program, INM-089. This program aims to investigate the potential of a canna-bi-nol (CBN) analog in treating Age-Related Macular Degeneration (AMD). The launch of INM-089 represents a significant expansion of InMed’s pipeline and offers hope for patients affected by this debilitating eye condition. (20)
INM-089 and AMD (20)
Age-Related Macular Degeneration is a prevalent cause of vision loss and potential blindness among individuals aged 50 and above. It affects approximately 35% of people aged 75 and older worldwide. AMD primarily targets the central vision and the ability to see fine details, making it a debilitating condition for those affected. There are two primary types of AMD: “dry” AMD, which accounts for roughly 90% of cases and is characterized by geographic atrophy (GA) in the macula, and “wet” AMD, which constitutes around 10% of cases and involves the development of excess vasculature that can lead to rapid blindness. Unfortunately, there is currently no cure for AMD, and the available treatment options aim to slow the disease’s progression.
InMed’s INM-089 program seeks to address this pressing medical need by developing a potential treatment for AMD. Early results from a study conducted in collaboration with canna-bi-noid expert Dr. Mauro Maccarrone at the Università degli Studi dell’Aquila in Italy are promising. The study demonstrated that INM-089 preserved retinal function in an in vivo AMD disease model. Furthermore, treatment with INM-089 improved the thickness of the outer nuclear layer (ONL) of the retina, where photoreceptors are located. The thickness of the ONL is closely correlated with photoreceptor preservation and visual acuity. (20)
Selecting the Right CBN Analog (20)
In the quest to find the most suitable candidate for AMD treatment, InMed Pharmaceuticals screened several CBN analog structures in both in vitro and in vivo models. Among these candidates, a specific CBN analog stood out, outperforming its natural canna-bi-noid counterpart and demonstrating promising effects related to AMD treatment. This discovery represents a significant step forward in the development of potential therapies for AMD, addressing a critical unmet medical need. (20)
The Role of INM-089 in Neuroprotection
One of the key attributes of INM-089 is its potential neuroprotective effect in the retina. By proactively protecting nerve cells at the back of the eye, particularly in the retinal area, INM-089 may preserve retinal function and vision in preclinical models. This neuroprotection is especially relevant in the context of AMD, where the degeneration of retinal cells contributes to vision loss.
InMed’s Scientific Advisor, Dr. Mauro Maccarrone, expressed optimism about the findings, stating, “Early studies show promising neuroprotective effects of INM-089, leading to the preservation of retinal function at the back of the eye. Neuroprotection in AMD remains an unmet medical need, and a new treatment option may help solve this multifactorial disease.” (20)
Expanding InMed’s Ocular Pipeline (20)
INM-089 represents the second ocular pharmaceutical program in InMed’s pipeline, with the first being INM-088, which focuses on glaucoma. This expansion into ocular therapies underscores InMed’s commitment to addressing a wide range of eye-related conditions, from front-of-eye to back-of-eye indications, including AMD.
InMed Pharmaceuticals Inc. (Nasdaq: INM) is making significant strides in the field of pharmaceutical research and development with its new program, INM-089, targeting the treatment of Age-Related Macular Degeneration. The promising results from early studies, including neuroprotective effects and retinal function preservation, provide hope for individuals affected by this debilitating eye condition. InMed’s commitment to expanding its ocular pipeline demonstrates its dedication to addressing unmet medical needs and improving the lives of patients with eye-related conditions. As research and development efforts continue, the potential for a new treatment option for AMD remains a beacon of hope for those living with this challenging disease.
InMed’s INM-089 program seeks to address this pressing medical need by developing a potential treatment for AMD. Early results from a study conducted in collaboration with canna-bi-noid expert Dr. Mauro Maccarrone at the Università degli Studi dell’Aquila in Italy are promising. The study demonstrated that INM-089 preserved retinal function in an in vivo AMD disease model. Furthermore, treatment with INM-089 improved the thickness of the outer nuclear layer (ONL) of the retina, where photoreceptors are located. The thickness of the ONL is closely correlated with photoreceptor preservation and visual acuity. (20)
InMed’s Scientific Advisor, Dr. Mauro Maccarrone, expressed optimism about the findings, stating, “Early studies show promising neuroprotective effects of INM-089, leading to the preservation of retinal function at the back of the eye. Neuroprotection in AMD remains an unmet medical need, and a new treatment option may help solve this multifactorial disease.” (20)
InMed Pharmaceuticals Inc. (Nasdaq: INM) is making significant strides in the field of pharmaceutical research and development with its new program, INM-089, targeting the treatment of Age-Related Macular Degeneration. The promising results from early studies, including neuroprotective effects and retinal function preservation, provide hope for individuals affected by this debilitating eye condition. InMed’s commitment to expanding its ocular pipeline demonstrates its dedication to addressing unmet medical needs and improving the lives of patients with eye-related conditions. As research and development efforts continue, the potential for a new treatment option for AMD remains a beacon of hope for those living with this challenging disease.
Behind the success of InMed Pharmaceuticals Inc. (Nasdaq: INM) and BayMedica lies a team of experts in the field of canna-bi-noids: (11)
Eric A. Adams, CEO: With over 30 years of experience in global biopharma leadership, Eric Adams leads the company’s strategic vision.
Alexandra Mancini, SVP: Alexandra brings 30+ years of global biopharma R&D experience to the table, overseeing clinical and regulatory affairs. (11)
Michael Woudenberg, COO: Michael’s 20+ years of engineering and manufacturing experience ensure efficient and scalable production. (11)
Eric Hsu, SVP, Preclinical R&D: With 20+ years of scientific leadership in gene transfer technologies, Eric drives preclinical research. (11)
Phil Barr, Senior Consultant: Phil offers strategic planning expertise, having worked with top-tier companies in the pharmaceutical industry. (11)
Colin Clancy, VP, IR & Corp Communications: Colin’s financial and investor relations background ensures transparent communication with stakeholders. (11)
Alexandra Mancini, SVP: Alexandra brings 30+ years of global biopharma R&D experience to the table, overseeing clinical and regulatory affairs. (11)
Michael Woudenberg, COO: Michael’s 20+ years of engineering and manufacturing experience ensure efficient and scalable production. (11)
Eric Hsu, SVP, Preclinical R&D: With 20+ years of scientific leadership in gene transfer technologies, Eric drives preclinical research. (11)
Phil Barr, Senior Consultant: Phil offers strategic planning expertise, having worked with top-tier companies in the pharmaceutical industry. (11)
Colin Clancy, VP, IR & Corp Communications: Colin’s financial and investor relations background ensures transparent communication with stakeholders. (11)
Looking ahead, InMed Pharmaceuticals aims to evaluate commercial partnerships, advance its ocular program, select candidates for its neurodegenerative disease program, and identify and execute strategic partnerships. These initiatives reflect the company’s commitment to driving innovation and making a lasting impact on the pharmaceutical landscape.
As they continue to explore the therapeutic applications of rare canna-bi-noids, they are poised to make further breakthroughs, offering hope to those in need of novel treatments.
As they continue to explore the therapeutic applications of rare canna-bi-noids, they are poised to make further breakthroughs, offering hope to those in need of novel treatments.
How This Company’s Rare Plant Expertise Could Potentially Disrupt a Multi-Billion Dollar Market (1)
See why now could be the best time to start your research on InMed Pharmaceuticals Inc. (Nasdaq: INM).
1. Active Chart
InMed Pharmaceuticals Inc. (Nasdaq: INM) has demonstrated the potential for significant upside potential with a 52-week range of $.2913 - $3.03. Not that any returns to previous highs are certain, but the potential for 940% upside suggests a strong reason to begin your research on this company after their shares fell from their 52-week high on 1/4/2023 to a recent 52-week low bounce on 11/20/2023. (6)
2. Groundbreaking Potential:
With its innovative approach to Alzheimer's disease treatment through INM-901 and its pioneering work in the treatment of Age-Related Macular Degeneration with INM-089, InMed Pharmaceuticals Inc. (Nasdaq: INM) presents groundbreaking potential across multiple therapeutic fronts. INM-901, in particular, has demonstrated unique pharmacological effects in preclinical studies, including neuroprotection and enhanced neuronal function. Exploring the research on INM-901 and INM-089 may reveal the prospect of substantial breakthroughs in the fields of Alzheimer's and AMD treatments. (17)(20)
3. Revenue-Generating Subsidiary
Having a revenue-generating subsidiary, InMed Pharmaceuticals Inc. (Nasdaq: INM) enjoys a unique advantage among pharmaceutical companies. This subsidiary provides a financial foundation for enhancing the company's ability to fund ongoing research and development activities without relying solely on external financing. (5)(11)
4. Expertise in Canna-bi-noid Manufacturing
With the growing interest in canna-bi-noids for various medical and market sectors, InMed Pharmaceuticals Inc. (Nasdaq: INM) has significant expertise in developing innovative manufacturing approaches for producing canna-bi-noids. This know-how positions InMed well to produce canna-bi-noids for various market sectors. (11)
5. Significant Valuation Gap
Despite its promising pipeline and revenue-generating subsidiary, InMed Pharmaceuticals Inc. (Nasdaq: INM)’s market capitalization remains below $5 million as of 11/17/2023, according to the company’s corporate presentation.(22 )This valuation gap suggests that the company could be trading well below its true intrinsic value, making it an intriguing research opportunity for those seeking undervalued assets.
6. Listed on Nasdaq Exchange
Being listed on a major exchange brings increased visibility, liquidity, and credibility, offering distinct advantages for a company. InMed Pharmaceuticals Inc. (Nasdaq: INM)'s presence on the Nasdaq exchange sets it apart from many cann-a-bis-related companies, which often trade on smaller or less-regulated exchanges. (13)
7. Rare Canna-bi-noid Production
Through its wholly owned subsidiary, BayMedica, InMed Pharmaceuticals Inc. (Nasdaq: INM) produces highly pure rare canna-bi-noids such as d9-T-H-CV, CBC, C-B-DV, and CBT for the consumer health and wellness industry. As the demand for these unique canna-bi-noids grows, InMed could be well-positioned to supply these valuable compounds to an expanding market. (11)
Sources:
Source 1: https://tinyurl.com/4jbezm8a
Source 2: https://tinyurl.com/yrvjvctz
Source 3: https://static.seekingalpha.com/uploads/2016/8/8/42544696-14707022875232582_origin.jpg
Source 4: https://tinyurl.com/57det22r
Source 5: https://finance.yahoo.com/news/inmed-pharmaceuticals-reports-full-fiscal-172100106.html
Source 6: https://www.barchart.com/stocks/quotes/INM/price-history/historical
Source 7: https://finviz.com/quote.ashx?t=INM&p=d
Source 8: https://schrts.co/ZuNTmSGx
Source 9: https://www.sofi.com/learn/content/understanding-low-float-stocks/
Source 10: https://www.inmedpharma.com/wp-content/uploads/2023/04/InMed-Wide-logo-Web.png
Source 11: https://www.inmedpharma.com/wp-content/uploads/2023/02/InMed-Corporate-Deck-October-2023.pdf
Source 12: https://www.marketwatch.com/investing/stock/inm?mod=search_symbol
Source 13: https://www.nasdaq.com/solutions/listings/markets/nordics/main-market#:~:text=A%20listing%20on%20the%20Main,the%20company%20and%20its%20business.
Source 14: https://www.investopedia.com/terms/n/nanocap.asp
Source 15: https://www.benzinga.com/money/best-nano-cap-stocks
Source 16: https://www.globexmarkets.com/financial-terms/n/nano-cap-stock.html
Source 17: https://finance.yahoo.com/news/inmed-pharmaceuticals-inc-inm-901-113000705.html
Source 18: https://finance.yahoo.com/news/inmed-reports-first-quarter-fiscal-130400163.html
Source 19: https://finance.yahoo.com/news/inmed-pharmaceuticals-announces-closing-5-231500164.html
Source 20: https://finance.yahoo.com/news/inmed-expands-pharmaceutical-pipeline-inm-130000663.html
Source 21: https://www.inmedpharma.com/pharmaceutical/inm-089-for-age-related-macular-degeneration/
Source 22: https://www.inmedpharma.com/wp-content/uploads/2023/02/InMed-Corporate-Deck-November-2023-Final.pdf